"I am delighted to join Connect and have been impressed by the potential of rademikibart to transform the treatment paradigm for acute and chronic asthma and COPD patients. I look forward to working closely with the team to guide the Company's development efforts and chart a course for long-term commercial success," said Mr. Schoeneck. Mr. Schoeneck is an accomplished biotech leader with more than 40 years of experience developing and commercializing breakthrough medicines and guiding companies through sign ...

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [2] - The company develops orally administered and topical gel products to deliver complex molecules, providing alternatives to invasive standard therapies [2] - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these products [2] Product Development - The company is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [2] - An early-stage epinephrine prodrug topical gel product candidate is also in development for various dermatological conditions, including alopecia areata [2] Upcoming Events - The management team of Aquestive will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 9, 2025, which will include panels on key therapeutic themes in immunology, inflammation, and metabolism [1]

Core Viewpoint - Idorsia Ltd. has announced a significant milestone in its collaboration with Simcere Pharmaceuticals, with the approval of QUVIVIQ (daridorexant) for insomnia treatment in China, leading to a milestone payment of USD 50 million and updated licensing terms [2][5][6]. Group 1: Approval and Licensing Agreement - Simcere Pharmaceuticals has received approval from the Chinese National Medical Products Administration for QUVIVIQ, which treats adult patients with insomnia without psychotropic drug control labeling [2][5]. - Idorsia and Simcere have updated their licensing agreement for QUVIVIQ in China, which includes an approval milestone payment of USD 50 million and potential commercial milestone payments of up to USD 93 million [3][5][6]. - The agreement allows Simcere exclusive rights to develop and commercialize QUVIVIQ in the Greater China region, which includes Mainland China, Hong Kong, and Macau [6]. Group 2: Company Statements and Future Plans - André C. Muller, CEO of Idorsia, praised the collaboration with Simcere, highlighting the rapid approval process of 2.5 years since the signing of the license agreement, and expressed optimism about QUVIVIQ becoming a global brand [4]. - Ren Jinsheng, Chairman and CEO of Simcere, emphasized the importance of the clinical results that enabled the approval and the commitment to making QUVIVIQ available to patients suffering from chronic insomnia [5]. - Arno Groenewoud, CFO of Idorsia, noted that the updated agreement reflects Simcere's confidence in QUVIVIQ's potential and their significant investment in the approval process [6].